NASDAQ:MDGL • US5588681057
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for MADRIGAL PHARMACEUTICALS INC (MDGL).
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2026-02-20 | B of A Securities | Maintains | Neutral -> Neutral |
| 2026-01-28 | Barclays | Initiate | Overweight |
| 2026-01-20 | Citizens | Maintains | Market Outperform -> Market Outperform |
| 2025-12-19 | Piper Sandler | Maintains | Overweight -> Overweight |
| 2025-12-11 | B. Riley Securities | Maintains | Buy -> Buy |
| 2025-11-21 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2025-11-20 | Oppenheimer | Maintains | Outperform -> Outperform |
| 2025-11-19 | Truist Securities | Maintains | Buy -> Buy |
| 2025-11-13 | Canaccord Genuity | Maintains | Buy -> Buy |
| 2025-11-11 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2025-11-05 | Citizens | Maintains | Market Outperform -> Market Outperform |
| 2025-11-05 | Cantor Fitzgerald | Upgrade | Neutral -> Overweight |
| 2025-11-03 | B of A Securities | Upgrade | Underperform -> Neutral |
| 2025-10-15 | Truist Securities | Initiate | Buy |
| 2025-10-15 | Piper Sandler | Maintains | Overweight -> Overweight |
| 2025-10-10 | Oppenheimer | Maintains | Outperform -> Outperform |
| 2025-09-29 | B. Riley Securities | Maintains | Buy -> Buy |
| 2025-09-12 | Canaccord Genuity | Maintains | Buy -> Buy |
| 2025-08-26 | TD Cowen | Maintains | Buy -> Buy |
| 2025-08-20 | JMP Securities | Maintains | Market Outperform -> Market Outperform |
| 2025-08-12 | UBS | Maintains | Buy -> Buy |
| 2025-08-06 | Canaccord Genuity | Maintains | Buy -> Buy |
| 2025-05-02 | UBS | Maintains | Buy -> Buy |
| 2025-05-02 | B. Riley Securities | Reiterate | Buy -> Buy |
| 2025-05-02 | Canaccord Genuity | Maintains | Buy -> Buy |
| 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 180.133M | 958.403M 432.05% | 1.517B 58.28% | 2.227B 46.80% | 3.111B 39.69% | 3.984B 28.06% | 4.88B 22.49% | 5.334B 9.30% | 5.976B 12.04% | 6.027B 0.85% | ||
| EBITDA YoY % growth | -379.969M -29.62% | -496.779M -30.74% | -298.591M 39.89% | -170.473M 42.91% | 377.35M 321.36% | 918.14M 143.31% | N/A | N/A | N/A | N/A | N/A | |
| EBIT YoY % growth | -380.496M -29.60% | -497.875M -30.85% | -300.097M 39.72% | -118.982M 60.35% | 354.48M 397.93% | 944.21M 166.36% | 1.752B 85.55% | 2.551B 45.61% | 3.02B 18.38% | 3.564B 18.01% | 3.534B -0.84% | |
| Operating Margin | N/A | -276.39% | -31.31% | -7.84% | 15.92% | 30.35% | 43.98% | 52.27% | 56.62% | 59.64% | 58.64% | |
| EPS YoY % growth | -19.94 -15.73% | -22.11 -10.88% | -12.75 42.33% | -4.80 62.32% | 11.89 347.52% | 33.85 184.67% | 59.15 74.76% | 83.94 41.91% | 108.70 29.49% | 136.13 25.23% | 152.87 12.30% |
All data in USD
| Q1 / 26 | Q2 / 26 | Q3 / 26 | Q4 / 26 | Q1 / 27 | Q2 / 27 | Q3 / 27 | Q4 / 27 | |
|---|---|---|---|---|---|---|---|---|
| EPS Q2Q % growth | -4.16 -25.40% | -0.85 55.30% | 1.13 122.77% | 1.99 177.45% | 5.37 228.87% | 8.58 1,110.05% | 11.33 903.00% | 14.10 608.51% |
| Revenue Q2Q % growth | 307.01M 123.69% | 356.16M 67.37% | 396.41M 37.99% | 435.99M 35.79% | N/A | N/A | N/A | N/A |
| EBITDA Q2Q % growth | -97.92M -24.06% | -69.457M -49.54% | 35.953M 131.86% | N/A | N/A | N/A | N/A | N/A |
| EBIT Q2Q % growth | -98.023M -23.59% | -25.571M 45.83% | 28.048M 124.61% | 53.792M 190.24% | N/A | N/A | N/A | N/A |
All data in USD
23 analysts have analysed MDGL and the average price target is 671.77 USD. This implies a price increase of 52.27% is expected in the next year compared to the current price of 441.16.
MADRIGAL PHARMACEUTICALS INC (MDGL) will report earnings on 2026-04-29, before the market open.
The consensus EPS estimate for the next earnings of MADRIGAL PHARMACEUTICALS INC (MDGL) is -4.16 USD and the consensus revenue estimate is 307.01M USD.
The expected long term growth rate for MADRIGAL PHARMACEUTICALS INC (MDGL) is 47.55%.